ライフサイエンスコーパス: transthyretin

1 europathy were identified, 60 primary and 41 transthyretin.

2 tion of the beta-Amyloid Peptide Abeta42 and transthyretin.

3 n in the peripheral nervous system of mutant transthyretin.

4 y-binding to the thyroxine-carrying protein, transthyretin.

5 erence (RNAi) could reduce the production of transthyretin.

6 ial infiltration, usually by light chains or transthyretin.

7 xplorations of pathological conformations of transthyretin.

8 hibits amyloid formation by both WT and L55P transthyretin.

9 raction between RBP4 and its binding partner transthyretin.

10 c fragment of the disease-associated protein transthyretin.

11 biophysical properties to recombinant human transthyretin.

12 r seed further amyloid aggregation of native transthyretin.

13 In preeclampsia, the serum levels of transthyretin, a carrier protein for thyroxine, are elev

14 etroaldolase, a de novo designed enzyme, and transthyretin, a nonenzyme protein.

15 Herein, we provide evidence that transthyretin, a transporter of thyroxine and retinol, i

16 eover, the treatment increased expression of transthyretin, accompanied by reduction of intracellular

17 s and Schwann cells of nerves with deposited transthyretin aggregates but the pattern also extended t

18 We demonstrate that transthyretin aggregates form deposits in preeclampsia p

19 Transthyretin aggregation-associated proteotoxicity appe

20 Hereditary transthyretin amyloid (ATTR) amyloidosis is a rare but f

21 in a reticular/pericellular pattern, whereas transthyretin amyloid (ATTR) more commonly showed patchy

22 All 6 patients had wild-type transthyretin amyloid (mean age 75 years; range, 69-85;

23 o reactivity to the Abeta precursor protein, transthyretin amyloid aggregates, or irrelevant proteins

24 Transthyretin amyloid cardiomyopathy (ATTR-CM) is an und

25 Transthyretin amyloid cardiomyopathy (ATTR-CM) results i

26 an) has been repurposed for the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM).

27 model of patients with wild-type or variant transthyretin amyloid cardiomyopathy and heart failure (

28 Treating all eligible patients with transthyretin amyloid cardiomyopathy in the United State

29 In patients with transthyretin amyloid cardiomyopathy, tafamidis reduces

30 resulting from aggregation and deposition of transthyretin amyloid fibrils in various tissues.

31 s study explored the prevalence of wild-type transthyretin amyloid in cAS by myocardial biopsy, its i

32 used by the deposition of hepatocyte-derived transthyretin amyloid in peripheral nerves and the heart

33 lonal immunoglobulin light-chain amyloid and transthyretin amyloid.

34 The transthyretin amyloidoses (ATTR) are invariably fatal di

35 The transthyretin amyloidoses appear to be caused by rate-li

36 , 37%), localized AL (N = 3, 10%), wild-type transthyretin amyloidosis (ATTR) (N = 1, 3.3%), and amyl

37 Transthyretin amyloidosis (ATTR) is a heterogeneous diso

38 Recent studies have suggested that transthyretin amyloidosis (ATTR) is a more common cause

39 Cardiac transthyretin amyloidosis (ATTR) is an increasingly reco

40 Hereditary transthyretin amyloidosis (ATTR) is usually characterise

41 tion (LTx) has been performed for hereditary transthyretin amyloidosis (ATTR) since 1990.

42 mically to bind human AA, ALkappa, ALlambda, transthyretin amyloidosis (ATTR), and Abeta amyloid depo

43 Cardiomyopathy is a manifestation of transthyretin amyloidosis (ATTR), which is an underrecog

44 for cardiac light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR).

45 Heart failure caused by wild-type transthyretin amyloidosis (ATTRwt) is an underappreciate

46 In univariable analyses, the presence of transthyretin amyloidosis amyloid had the highest hazard

47 epidemiology, and therapeutic strategies for transthyretin amyloidosis and highlight diagnostic pitfa

48 kilogram of body weight) in 32 patients with transthyretin amyloidosis and then evaluated ALN-TTR02 (

49 Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an

50 e, oral TTR stabilizer under development for transthyretin amyloidosis cardiomyopathy (ATTR-CM) that

51 years) using inputs from the ATTR-ACT trial (Transthyretin Amyloidosis Cardiomyopathy Clinical Trial)

52 Transthyretin amyloidosis is a fatal disorder that is ch

53 Transthyretin amyloidosis is a rare, life-threatening di

54 Transthyretin amyloidosis is caused by the deposition of

55 common treatment of patients with hereditary transthyretin amyloidosis is liver transplantation.

56 Treatment of transthyretin amyloidosis is typically focused on sympto

57 United States by using data from the THAOS (Transthyretin Amyloidosis Outcomes Survey) registry.

58 who when compared with whites with wild-type transthyretin amyloidosis, a phenotypically similar cond

59 For patients with transthyretin amyloidosis, there are numerous therapies

60 eported as the cause of the life-threatening transthyretin amyloidosis.

61 was informative in only 40% of patients with transthyretin amyloidosis.

62 loped pharmacological treatment dedicated to transthyretin amyloidosis.

63 esidues 105-115 of the amyloidogenic protein transthyretin and a DNA origami construct is used to for

64 11-residue peptide derived from the protein transthyretin and clusters of this fibre-forming peptide

65 loidogenesis, we produced recombinant murine transthyretin and human/murine transthyretin heterotetra

66 y showed that the placenta actively produces transthyretin and in preeclampsia, a significant amount

67 here were 28 patients (25 men) with Ala97Ser transthyretin and late onset (59.9 +/- 6.0 years) disabl

68 Transthyretin and light-chain amyloidosis are the 2 main

69 dence for a causal link between dysregulated transthyretin and preeclampsia.

70 olipoproteins, complement C4-A, haptoglobin, transthyretin and serotransferrin.

71 4 patients: 5 amyloid light chain, 5 amyloid transthyretin, and 4 control with hypertensive heart dis

72 he plasma proteins, fibrinogen, fibronectin, transthyretin, and alpha-fetoprotein, an essential featu

73 tetrameric protein complexes (streptavidin, transthyretin, and hemoglobin) in the gas phase was unde

74 in three unrelated amyloid species: Abeta42, transthyretin, and human islet amylin polypeptide.

75 e case of those formed from serum amyloid A, transthyretin, and islet amyloid polypeptide.

76 mon systemic amyloidoses (ALlambda, ALkappa, transthyretin, and reactive amyloidosis), with Congo red

77 n techniques with primers designed to detect transthyretin, apolipoprotein AI, apolipoprotein AII, fi

78 (Transthyretin-Associated Amyloidoses Outcome Survey [THA

79 f diagnosis and 25% of patients with amyloid transthyretin (ATTR) amyloidosis die within 24 months of

80 Cardiac transthyretin (ATTR) amyloidosis is a progressive and fa

81 oidosis, immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially infl

82 onoclonal immunoglobulin light-chain (AL) or transthyretin (ATTR) type-and healthy volunteers (n = 5)

83 e C, holo hemoglobin-alpha, ovalbumin, human transthyretin, avidin, bovine serum albumin, concanavali

84 lity in CA, with an amyloid burden effect in transthyretin, but an idiosyncratic effect in light chai

85 tole correlated with extracellular volume in transthyretin, but not light chain amyloidosis.

86 d burden measured by extracellular volume in transthyretin, but not light chain amyloidosis.

87 d qRT-PCR, we investigated the production of transthyretin by preeclamptic placentae and whether tran

88 id systems, beta-amyloid peptide (Abeta) and transthyretin, by these designed alpha-sheet peptides.

89 Transthyretin-CA (ATTR) was diagnosed by DPD and absence

90 nd that changes in the tertiary structure of transthyretin can be associated with disruptions to the

91 Occult wild-type transthyretin cardiac amyloid had a prevalence of 6% amo

92 Wild-type transthyretin cardiac amyloid is also a disorder of agei

93 Importance: Transthyretin cardiac amyloidosis (also known as ATTR ca

94 Transthyretin cardiac amyloidosis (ATTR) is an underreco

95 Wild-type transthyretin cardiac amyloidosis (ATTRwt) is increasing

96 st common of these conditions, but wild-type transthyretin cardiac amyloidosis (ATTRwt) is increasing

97 Technetium-99 m pyrophosphate protocols for transthyretin cardiac amyloidosis diagnosis have variabl

98 ing have transformed our ability to diagnose transthyretin cardiac amyloidosis noninvasively and unma

99 registry analysis of patients with suspected transthyretin cardiac amyloidosis referred for technetiu

100 tic curve of more than 0.96 for diagnosis of transthyretin cardiac amyloidosis.

101 primarily affects the peripheral nerves, and transthyretin cardiomyopathy (TTR-CM), which primarily a

102 ongoing phase 3 ATTR-ACT study (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial), an interna

103 Compared to primary cases, transthyretin cases had longer survival, longer time to

104 Twenty transthyretin cases were found to have Val30Met mutation

105 Systemic amyloid deposition of aggregated transthyretin causes hereditary and sporadic amyloidoses

106 old, found in many proteins belonging to the Transthyretin clan of Pfam.

107 c placentae secreted similar levels of total transthyretin compared to normotensive placentae (2352 +

108 These observations explain the lack of transthyretin deposition in transgenics carrying a low c

109 Moreover, when preventing nonfibrillar transthyretin deposition with anakinra or transthyretin

110 uction of both mutant and nonmutant forms of transthyretin, establishing proof of concept for RNAi th

111 neuropathy (SFN) is an important feature of transthyretin familial amyloid polyneuropathy (TTR-FAP).

112 Transthyretin familial amyloid polyneuropathy is a hered

113 een shown to delay neurologic progression of transthyretin familial amyloid polyneuropathy, there are

114 ate phenotypic presentations of the disease: transthyretin familial amyloid polyneuropathy, which pri

115 IBG imaging is a useful prognostic marker in transthyretin familial amyloid polyneuropathy.

116 etic denervation detected by MIBG imaging in transthyretin familial amyloid polyneuropathy.

117 ology and thermodynamic stability of natural transthyretin fibrils with those of fibrils generated in

118 We determined genotype status for the transthyretin gene (TTR) in 3856 black participants in t

119 A novel mutation in the transthyretin gene (TTR) in Indian patients with familia

120 Silencing the murine transthyretin gene in the presence of the L55P human gen

121 siRNAs are being explored to knock-down the transthyretin gene to prevent the related form of amyloi

122 he noncovalently associated complex of human transthyretin, generated by collision-induced dissociati

123 nsgenics carrying a low copy number of human transthyretin genes.

124 The aggregation of transthyretin has been reported as the cause of the life

125 These findings suggest that transthyretin has earlier and greater predilection for n

126 binant murine transthyretin and human/murine transthyretin heterotetramers and compared their structu

127 PP, neprilysin, insulin-degrading enzyme and transthyretin in MCAT, AbetaPP, MCAT/AbetaPP and wild-ty

128 The increased aggregation of transthyretin in preeclampsia occurs at the post-transcr

129 ion of retinol-binding protein 4 (RBP4) with transthyretin in the serum would reduce serum RBP4 and r

130 fferent sources (alpha-synuclein, Sup35, and transthyretin) induced NADPH oxidase-dependent NETs in v

131 Native transthyretin inhibits all preeclampsia-like features in

132 critical conformational changes at the RBP4-transthyretin interface.

133 The tetrameric protein transthyretin is a transporter of retinol and thyroxine

134 We found that the sequestering agent transthyretin is able to bind the toxic Abeta(1-42) spec

135 yretin by preeclamptic placentae and whether transthyretin is carried into the maternal circulation v

136 Murine transthyretin is not amyloidogenic because the native ho

137 aggregation of circulating proteins, such as transthyretin, is a severe and usually fatal condition.

138 ecursor proteins, including serum amyloid A, transthyretin, islet amyloid polypeptide, and amyloid be

139 Transthyretin isolated from preeclamptic serum is also a

140 in 3xTg-AD mice and increasing expression of transthyretin, known to inhibit Abeta aggregation.

141 For ALN-TTR02, the mean reductions in transthyretin levels at doses of 0.15 to 0.3 mg per kilo

142 pid, dose-dependent, and durable lowering of transthyretin levels was observed in the two trials.

143 phase 1 trial to assess safety and effect on transthyretin levels.

144 We show here that the monomeric transthyretin-like domain of human carboxypeptidase D ag

145 common Greek-key beta sandwich fold with two transthyretin-like repeats that polymerize into a pilus

146 nts included urinary protein 1 (m/z=15,835), transthyretin (m/z=13,880), and a component at m/z=13,35

147 Hereditary transthyretin-mediated (hATTR) amyloidosis is a rapidly

148 Hereditary transthyretin-mediated amyloidosis is a rare, inherited,

149 TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy.

150 e safety profile in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy.

151 rtitioning of destabilized retroaldolase and transthyretin mutants between the aforementioned conform

152 A total of 143 individuals with V30M transthyretin mutation underwent Holter, ambulatory bloo

153 ly variable and influenced by the underlying transthyretin mutation, age of the affected individual,

154 Val122Ile is the most common transthyretin mutation, and neurologic phenotypic expres

155 arterial pressure, but not the presence of a transthyretin mutation, were independently associated wi

156 c failure and is due to dominantly inherited transthyretin mutations causing accelerated amyloid depo

157 opathy caused by extracellular deposition of transthyretin, normally involved in the transportation o

158 in amyloidosis without typical signs, senile transthyretin, or hereditary amyloidosis with a concomit

159 wing targets will be specifically discussed: transthyretin, p53, superoxide dismutase 1, lysozyme, se

160 titrypsin, complement factor B, haptoglobin, transthyretin, plasma retinol binding protein, albumin,

161 hat the murine protein interacted with human transthyretin, preventing the dissociation and partial u

162 ulf2 in hepatocytes under the control of the transthyretin promoter.

163 underrecognized systemic disease whereby the transthyretin protein misfolds to form fibrils that depo

164 arallel phagocytic pathway that includes the transthyretin protein TTR-52, as well as CED-7, NRF-5 an

165 ne-to-isoleucine substitution (V122I) in the transthyretin protein, which has been associated with la

166 tiating immunoglobulin light-chain (AL) from transthyretin-related cardiac amyloidoses (ATTR) is impe

167 Transthyretin-related cardiac amyloidosis is a progressi

168 monomer unfolding of the human serum protein transthyretin, resulting in aggregation and extracellula

169 ement, recombinant thyroid transport protein transthyretin (rTTR), and dedicated modes of liquid chro

170 e to aggregation and deposition of wild-type transthyretin (senile systemic amyloidosis, SSA) or mono

171 C, prenylcysteine oxidase 1, paraoxonase 1, transthyretin, serum amyloid A4, and fibrinogen alpha ch

172 w in immunized mice that the carrier protein transthyretin simultaneously optimizes three factors: ef

173 ar transthyretin deposition with anakinra or transthyretin siRNA, Pcdh10 protein levels were reduced,

174 Our findings suggest that a focus on transthyretin structure and function is a novel strategy

175 rs otherwise composed of human amyloid-prone transthyretin subunits imposes kinetic stability, preven

176 We show that certain beta-strands in transthyretin tend to unfold and sample nonnative confor

177 s of two protein complexes, source-activated transthyretin tetramer and nativelike serum amyloid P de

178 chemical or mutational stabilization of the transthyretin tetramer does not hinder amyloid seeding.

179 tion approach was applied to generate intact transthyretin tetramers with charge states ranging from

180 enta, they may also be delivering aggregated transthyretin to specific maternal organs, contributing

181 residue segment of the amyloidogenic protein transthyretin (TTR(105-115)).

182 ic oligomeric intermediates populated during transthyretin (TTR) aggregation process.

183 sion of the human systemic amyloid precursor transthyretin (TTR) ameliorates Alzheimer's disease (AD)

184 Hereditary transthyretin (TTR) amyloid cardiomyopathy (hATTR-CM) du

185 It is well established that the formation of transthyretin (TTR) amyloid fibrils is linked to the des

186 ulfated GAGs, especially heparin, accelerate transthyretin (TTR) amyloidogenesis by quaternary struct

187 Transthyretin (TTR) amyloidogenesis inhibitors are typic

188 To develop potent transthyretin (TTR) amyloidogenesis inhibitors that also

189 To develop potent and highly selective transthyretin (TTR) amyloidogenesis inhibitors, it is us

190 Transthyretin (TTR) amyloidogenesis requires rate-limiti

191 Transthyretin (TTR) amyloidoses are familial or sporadic

192 LTx) is an accepted treatment for hereditary transthyretin (TTR) amyloidosis (ATTR).

193 Transthyretin (TTR) amyloidosis is a progressive systemi

194 Transthyretin (TTR) amyloidosis is an underdiagnosed dis

195 g transcriptional profiling, we now identify transthyretin (TTR) and Klotho as APP/APLP2-dependent ge

196 g retinol levels, which are located near the transthyretin (TTR) and retinol binding protein 4 (RBP4)

197 gating oligomerization and ligand binding of transthyretin (TTR) and the chaperone domain from prosur

198 either wild-type (ATTRwt) or mutant (ATTRm) transthyretin (TTR) CA.

199 Wild-type and mutant transthyretin (TTR) can misfold and deposit in the heart

200 th retinoids for RBP4 binding, disrupts RBP4-transthyretin (TTR) complexes, and results in urinary se

201 on studies were carried out as a function of transthyretin (TTR) concentration to quantify the thermo

202 Among them, the transthyretin (TTR) concentration was highly increased i

203 promotes degradation of the nonglycosylated transthyretin (TTR) D18G misfolded client.

204 ommon familial amyloid polyneuropathy (FAP), transthyretin (TTR) displays this role primarily affecti

205 Five groups of patients were studied: (1) transthyretin (TTR) familial amyloidotic polyneuropathy

206 The tetrameric thyroxine transport protein transthyretin (TTR) forms amyloid fibrils upon dissociat

207 Transthyretin (TTR) forms misfolded beta-sheet aggregate

208 of valine for isoleucine at codon 122 of the transthyretin (TTR) gene (V122I), present in 3.43% of Af

209 The siRNAs were designed to silence the transthyretin (Ttr) gene and were conjugated to a trival

210 ogressive disease caused by mutations in the transthyretin (TTR) gene.

211 caused by aggregation of Ig light chains or transthyretin (TTR) in the cardiac interstitium and cond

212 ion of retinol-binding protein 4 (RBP4) with transthyretin (TTR) in the serum may decrease the uptake

213 rgeting human apolipoprotein C-III and human transthyretin (TTR) in transgenic mice.

214 of a GalNAc conjugate duplex targeting mouse transthyretin (TTR) indicated that GNA is well tolerated

215 he proposed mechanism of fibril formation of transthyretin (TTR) involves self-assembly of partially

216 Transthyretin (TTR) is a blood and cerebrospinal fluid t

217 Circulating transthyretin (TTR) is a critical determinant of plasma

218 Transthyretin (TTR) is a homotetramer that circulates in

219 Transthyretin (TTR) is a homotetrameric protein.

220 Transthyretin (TTR) is a homotetrameric transport protei

221 Transthyretin (TTR) is a largely beta-sheet serum protei

222 Transthyretin (TTR) is a plasma homotetrameric protein i

223 Transthyretin (TTR) is a thyroxine-transport protein fou

224 Transthyretin (TTR) is an abundant homotetrameric serum

225 Human transthyretin (TTR) is an amyloidogenic protein whose ag

226 Transthyretin (TTR) is an amyloidogenic protein, the amy

227 Human transthyretin (TTR) is an amyloidogenic protein.

228 nt of l-thyroxine (T4) from binding sites on transthyretin (TTR) is considered a significant contribu

229 Kinetic stabilization of transthyretin (TTR) is established to prevent human neur

230 The visceral protein transthyretin (TTR) is frequently affected by oxidative

231 Human transthyretin (TTR) is implicated in several fatal forms

232 The human systemic amyloid precursor protein transthyretin (TTR) is known to inhibit amyloid-beta (Ab

233 The plasma protein transthyretin (TTR) is linked to human amyloidosis.

234 Transthyretin (TTR) is normally a stable plasma protein.

235 Transthyretin (TTR) is one of the many proteins that are

236 Wild type transthyretin (TTR) is responsible for senile systemic a

237 The amyloidogenic protein transthyretin (TTR) is thought to aggregate into amyloid

238 Increased neuronal synthesis of transthyretin (TTR) may favorably impact on Alzheimer's

239 The process of transthyretin (TTR) misfolding and aggregation, includin

240 Transthyretin (TTR) modulates the deposition, processing

241 The amyloidogenic homotetrameric protein transthyretin (TTR) must undergo rate-limiting dissociat

242 f familial amyloid polyneuropathy (FAP) with transthyretin (TTR) mutations.

243 asymptomatic individuals with amyloidogenic transthyretin (TTR) mutations.

244 ramer dissociation and monomer misfolding of transthyretin (TTR) occur before its aggregation into cr

245 The protective effect of transthyretin (TTR) on cellular toxicity of beta-amyloid

246 ntaining amyloid deposits composed of either transthyretin (TTR) or Ig light chain from nine patients

247 ting from myocardial deposition of misfolded transthyretin (TTR) or pre-albumin.

248 The Ser52Pro variant of transthyretin (TTR) produces aggressive, highly penetran

249 s with familial amyloidosis, mutation in the transthyretin (TTR) protein is the most common type.

250 Acidification of the transthyretin (TTR) tetramer facilitates dissociation an

251 Dissociation of the native transthyretin (TTR) tetramer is widely accepted as the c

252 The ability of transthyretin (TTR) to bind Abeta-peptides and the posit

253 In turn, holo-RBP associates in plasma with transthyretin (TTR) to form a ternary RBP-retinol-TTR co

254 nd vinyl sulfonamides that covalently modify transthyretin (TTR) tracelessly.

255 ection in vivo, overexpression of a WT human transthyretin (TTR) transgene was ameliorative in the AP

256 y for the inner thyroxine binding subsite of transthyretin (TTR) was conceived of by structure-based

257 sis is caused by an amyloidogenic variant of transthyretin (TTR) with a substitution of methionine fo

258 This is the case of transthyretin (TTR), a homotetrameric protein whose diss

259 ATTR are caused by aggregation of transthyretin (TTR), a natively tetrameric protein invol

260 Transthyretin (TTR), a systemic amyloid precursor in the

261 pete with thyroxin (T4) for binding sites on transthyretin (TTR), a T4 transport protein found in pla

262 roid hormone disrupting chemicals (THDCs) is transthyretin (TTR), a thyroid hormone transporter in ve

263 itive genes, alpha1-antitrypsin (alpha1-AT), transthyretin (TTR), and apolipoprotein B (ApoB) after i

264 protein complexes: C-reactive protein (CRP), transthyretin (TTR), and concanavalin A (Con A).

265 The wild type protein, transthyretin (TTR), and over 120 genetic TTR variants a

266 protein-protein interaction between RBP4 and transthyretin (TTR), another serum protein that protects

267 ng the binding of 2,4-dinitrophenol (DNP) to transthyretin (TTR), as well as preliminary measurements

268 the conformation of model proteins, namely, transthyretin (TTR), avidin, concanavalin A (conA), and

269 ic amyloidoses caused by mutant or wild-type transthyretin (TTR), deposition occurs at a distance fro

270 The misfolding of transthyretin (TTR), including rate-limiting tetramer di

271 Wild-type transthyretin (TTR), normally a soluble plasma-circulati

272 yloid fibril formation by the plasma protein transthyretin (TTR), requiring rate-limiting tetramer di

273 We determined the transthyretin (TTR)-binding activity of blood-accumulati

274 Compounds with transthyretin (TTR)-binding potency in the blood plasma

275 mice were crossbred with the liver-specific transthyretin (TTR)-IGF-I transgenic mice to assess the

276 Transthyretin (TTR)-related familial amyloid polyneuropa

277 a tertiary retinol binding protein 4 (RBP4)-transthyretin (TTR)-retinol complex.

278 f these chemicals is the hormone transporter transthyretin (TTR).

279 4-oxadiazole designed to bind selectively to transthyretin (TTR).

280 c" (ATTR) variants from mutant and wild-type transthyretin (TTR).

281 increase in the expression of TTR, encoding transthyretin (TTR).

282 d hormone (TH) thyroxine (T4) for binding to transthyretin (TTR).

283 porter of the secreted amyloidogenic protein transthyretin (TTR).

284 ) prion, and a short polypeptide fragment of transthyretin, TTR (105-115), directly correlates to the

285 ted Phase II/III trials for the treatment of Transthyretin Type Familial Amyloid Polyneuropathy (TTR-

286 d in 76 patients, including 56 with the wild transthyretin type, 17 with the mutant transthyretin typ

287 wild transthyretin type, 17 with the mutant transthyretin type, and 3 with the secondary type.

288 to probe conformations sampled by monomeric transthyretin under amyloidogenic conditions.

289 nuclein associated with Parkinson's disease, transthyretin V30M mutant associated with familial amylo

290 sgenic for few copies of amyloid-prone human transthyretin variants, including the aggressive L55P mu

291 of knockdown of the clinically relevant gene transthyretin was observed at doses as low as 0.03 mg/kg

292 01); levels of mutant and nonmutant forms of transthyretin were lowered to a similar extent.

293 Both total and aggregated transthyretin were present in higher levels in preeclamp

294 Increased levels of aggregated transthyretin were specifically associated to preeclampt

295 ins (all except BSA) and an impurity (bovine transthyretin) were confidently identified by database s

296 s, two peptides (serum amyloid A protein and transthyretin) were identified and quantitated by immuno

297 euritogenesis with a decreased expression of transthyretin, which is known to be downregulated by oxi

298 cedure, which replaces the patient's variant transthyretin with the WT protein, can fail to stop subs

299 of 1.0 mg per kilogram, ALN-TTR01 suppressed transthyretin, with a mean reduction at day 7 of 38%, as

300 amyloid polyneuropathy (FAP) due to mutated transthyretin, with sudomotor failure as a common manife